Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

@article{Ferrari2015SolitomabAE,
  title={Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE{\textregistered}), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro},
  author={F. Ferrari and S. Bellone and J. Black and Carlton L. Schwab and S. Lopez and E. Cocco and E. Bonazzoli and Federica Predolini and G. Menderes and B. Litkouhi and E. Ratner and D. Silasi and M. Azodi and P. Schwartz and A. Santin},
  journal={Journal of Experimental \& Clinical Cancer Research : CR},
  year={2015},
  volume={34}
}
BackgroundUterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely poor prognosis. We evaluated the expression levels of EpCAM and the in vitro activity of solitomab, a bispecific single-chain antibody construct which targets epithelial-cell-adhesion-molecule (EpCAM) on tumor cells and also contains a CD3 binding region, against primary uterine and ovarian CS cell lines.MethodsEpCAM expression was evaluated by flow cytometry in a total… Expand
Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition
Recent advances of bispecific antibodies in solid tumors
NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy
T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases
Genomics of gynaecological carcinosarcomas and future treatment options.
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
EpCAM: A New Therapeutic Target for an Old Cancer Antigen
CD133+ Cancer Stem Cell–like Cells Derived from Uterine Carcinosarcoma (Malignant Mixed Müllerian Tumor)
Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer
...
1
2
3
...